LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 4362

Search options

  1. Article ; Online: Germline Testing in Prostate Cancer: Implementation and Disparities of Care.

    Brown, Landon C / Armstrong, Andrew J

    JCO oncology practice

    2023  Volume 19, Issue 5, Page(s) 221–223

    MeSH term(s) Male ; Humans ; Prostatic Neoplasms/epidemiology ; Prostatic Neoplasms/therapy ; Prostatic Neoplasms/genetics ; Genetic Testing
    Language English
    Publishing date 2023-01-31
    Publishing country United States
    Document type Editorial ; Research Support, N.I.H., Extramural ; Comment
    ZDB-ID 3028198-2
    ISSN 2688-1535 ; 2688-1527
    ISSN (online) 2688-1535
    ISSN 2688-1527
    DOI 10.1200/OP.22.00804
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Impact of eradicating hepatitis C virus on the work productivity of chronic hepatitis C (CH-C) patients: an economic model from five European countries.

    Younossi, Z / Brown, A / Buti, M / Fagiuoli, S / Mauss, S / Rosenberg, W / Serfaty, L / Srivastava, A / Smith, N / Stepanova, M / Beckerman, R

    Journal of viral hepatitis

    2016  Volume 23, Issue 3, Page(s) 217–226

    Abstract: CH-C negatively affects work productivity (WP), creating a large economic burden. The aim ... patients in five European countries (EU5). Work Productivity and Activity Index-Specific Health Problem ...

    Abstract CH-C negatively affects work productivity (WP), creating a large economic burden. The aim of this study was to model the impact of sustained virologic response (SVR) on WP in CHC genotype 1 (GT1) patients in five European countries (EU5). Work Productivity and Activity Index-Specific Health Problem questionnaire was administered to patients across the ION clinical trials (n = 629 European patients). The analysis modelled a population of GT1 CHC patients over one year, who had been either not treated or treated with LDV/SOF. Sensitivity analyses assessed the possibility that CHC patients' labour costs were lower than the general population's and presented results by fibrosis stage. Before initiation of treatment, EU patients with CHC GT1 exhibited absenteeism and presenteeism impairments of 3.54% and 9.12%, respectively. About 91.8% of EU patients in the ION trials achieved SVR and improved absenteeism and presenteeism impairments by 16.3% and 19.5%, respectively. Monetizing these data, treatment with LDV/SOF resulted in an annual productivity gain of €435 million and a weighted average per-employed patient (PEP) gain of €900 in the EU5. PEP gains from treatment are projected to be higher in cirrhotic than in noncirrhotic patients. If CHC patients are assumed to earn 20% less than the general population, gains of €348 million (€720 PEP) annually are projected. CHC results in a significant economic burden to European society. Due to improvements in WP, SVR with treatment could provide substantial economic gains, partly offsetting the direct costs related to its widespread use.
    MeSH term(s) Adolescent ; Adult ; Aged ; Aged, 80 and over ; Antiviral Agents/therapeutic use ; Benzimidazoles/therapeutic use ; Disease Eradication ; Efficiency ; Europe ; Female ; Fluorenes/therapeutic use ; Genotype ; Hepacivirus/genetics ; Hepacivirus/isolation & purification ; Hepatitis C, Chronic/drug therapy ; Hepatitis C, Chronic/virology ; Humans ; Male ; Middle Aged ; Models, Economic ; Sofosbuvir/therapeutic use ; Surveys and Questionnaires ; Young Adult
    Chemical Substances Antiviral Agents ; Benzimidazoles ; Fluorenes ; ledipasvir (013TE6E4WV) ; Sofosbuvir (WJ6CA3ZU8B)
    Language English
    Publishing date 2016-03
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1212497-7
    ISSN 1365-2893 ; 1352-0504
    ISSN (online) 1365-2893
    ISSN 1352-0504
    DOI 10.1111/jvh.12483
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Has Mismatch Repair-Deficient Cancer Met Its MATCH?

    Brown, Landon C / Armstrong, Andrew J

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology

    2019  Volume 38, Issue 3, Page(s) 183–187

    MeSH term(s) Arm ; Colorectal Neoplasms ; DNA Mismatch Repair ; Humans ; Nivolumab
    Chemical Substances Nivolumab (31YO63LBSN)
    Language English
    Publishing date 2019-12-03
    Publishing country United States
    Document type Editorial ; Comment
    ZDB-ID 604914-x
    ISSN 1527-7755 ; 0732-183X
    ISSN (online) 1527-7755
    ISSN 0732-183X
    DOI 10.1200/JCO.19.02860
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: RNA-Based Homologous Recombination Deficiency Signature Detects Homologous Recombination Deficiency-RNA+ Patients With and Without Homologous Recombination Repair Gene Pathogenic Alterations in Men With Prostate Cancer.

    Brown, Landon C / Zhu, Jason / Mauer, Elizabeth / Thiede, Stephanie N / Macera, Lisa / Stein, Michelle M / Taxter, Timothy / Raghavan, Derek / Burgess, Earle F

    JCO precision oncology

    2023  Volume 7, Page(s) e2300378

    Abstract: Purpose: Homologous recombination deficiency (HRD) is a well-described phenotype of some prostate cancers; however, current biomarkers for HRD are imperfect and rely on detection of single gene alterations in the homologous recombination repair (HRR) ... ...

    Abstract Purpose: Homologous recombination deficiency (HRD) is a well-described phenotype of some prostate cancers; however, current biomarkers for HRD are imperfect and rely on detection of single gene alterations in the homologous recombination repair (HRR) pathway, which may not capture the complexity of HRD biology. RNA signature-based methods of HRD identification present a potentially dynamic assessment of the HRD phenotype; however, its relationship with HRR gene alterations is not well characterized in prostate cancer.
    Methods: A HRD assay on the basis of an RNA signature associated with biallelic
    Results: In this cohort, of the 126 (13%) patients found to be HRD+ by RNA signature (HRD-RNA+), 100 (79%) had no coexisting HRR gene alteration. Among samples with biallelic
    Conclusion: Use of an RNA-based HRD signature significantly expands the fraction of patients with prostate cancer who may derive benefit from poly (ADP-ribose) polymerase inhibitors (PARPis) compared with using HRR gene mutations alone. Further studies are needed to evaluate functional HRD significance and inform future usage as a predictive biomarker for PARPi selection.
    MeSH term(s) Male ; Humans ; BRCA1 Protein/genetics ; Recombinational DNA Repair/genetics ; Homologous Recombination/genetics ; Retrospective Studies ; BRCA2 Protein/genetics ; Prostatic Neoplasms/genetics ; Poly(ADP-ribose) Polymerase Inhibitors
    Chemical Substances BRCA1 protein, human ; BRCA1 Protein ; BRCA2 protein, human ; BRCA2 Protein ; Poly(ADP-ribose) Polymerase Inhibitors
    Language English
    Publishing date 2023-06-14
    Publishing country United States
    Document type Journal Article
    ISSN 2473-4284
    ISSN (online) 2473-4284
    DOI 10.1200/PO.23.00378
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: The Role of Targeted Therapy in the Management of High-Risk Resected Kidney Cancer: What Have We Learned and How Will It Inform Future Adjuvant Trials.

    Brown, Landon C / Zhang, Tian / George, Daniel J

    Cancer journal (Sudbury, Mass.)

    2020  Volume 26, Issue 5, Page(s) 376–381

    Abstract: The primary treatment for localized renal cell carcinoma (RCC) is surgical resection with curative intent. Despite this, many patients, especially those with high-risk features, will develop recurrent or metastatic disease. Antiangiogenic therapies ... ...

    Abstract The primary treatment for localized renal cell carcinoma (RCC) is surgical resection with curative intent. Despite this, many patients, especially those with high-risk features, will develop recurrent or metastatic disease. Antiangiogenic therapies targeting vascular endothelial growth factor have been a mainstay of treatment of advanced RCC for more than 10 years. Evidence supporting the use of these therapies in the adjuvant setting is mixed, although one clinical trial, S-TRAC, has shown improvements in disease-free survival with 1 year of adjuvant sunitinib among patients with clear cell histology and high-risk features, leading to the first US Food and Drug Administration approval of an adjuvant therapy for high-risk RCC patients. Further investigation into combination therapies with immunotherapy, neoadjuvant approaches, and patient selection will be key to determining optimal adjuvant therapy regimens to improve outcomes and increase cure rates for patients with localized RCC.
    MeSH term(s) Carcinoma, Renal Cell/drug therapy ; Carcinoma, Renal Cell/surgery ; Chemotherapy, Adjuvant ; Humans ; Immunotherapy ; Kidney Neoplasms/drug therapy ; Kidney Neoplasms/surgery ; Neoadjuvant Therapy ; Sunitinib/therapeutic use ; Vascular Endothelial Growth Factor A/antagonists & inhibitors
    Chemical Substances Vascular Endothelial Growth Factor A ; Sunitinib (V99T50803M)
    Language English
    Publishing date 2020-09-06
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 2018400-1
    ISSN 1540-336X ; 1528-9117 ; 1081-4442
    ISSN (online) 1540-336X
    ISSN 1528-9117 ; 1081-4442
    DOI 10.1097/PPO.0000000000000469
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Book: Court and civic society in the Burgundian Low Countries c. 1420 - 1530

    Brown, Andrew / Small, Graeme

    (Manchester Medieval sources series)

    2007  

    Author's details selected sources translated and annotated with an introduction by Andrew Brown and Graeme Small
    Series title Manchester Medieval sources series
    Language English
    Size VIII, 280 S., 1 Kt., 22 cm
    Edition 1. publ.
    Publisher Manchester Univ. Press
    Publishing place Manchester u.a.
    Document type Book
    ISBN 0719056209 ; 9780719056192 ; 9780719056208 ; 0719056195
    Database Former special subject collection: coastal and deep sea fishing

    More links

    Kategorien

  7. Article ; Online: The Immunotherapy Landscape in Renal Cell Carcinoma.

    Brown, Landon C / Desai, Kunal / Zhang, Tian / Ornstein, Moshe C

    BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy

    2020  Volume 34, Issue 6, Page(s) 733–748

    Abstract: The past 30 years have borne witness to a gradual evolution in the treatment landscape of advanced renal cell carcinoma (aRCC). Early immunotherapy approaches such as interferon-α and high-dose interleukin-2 (IL-2) therapy in this immunogenic tumor ... ...

    Abstract The past 30 years have borne witness to a gradual evolution in the treatment landscape of advanced renal cell carcinoma (aRCC). Early immunotherapy approaches such as interferon-α and high-dose interleukin-2 (IL-2) therapy in this immunogenic tumor provided durable responses in only a minority of patients and came with toxic side effects. A growing understanding of the tumor biology elucidated pathways of tumorigenesis, which in turn revealed novel targets amenable to targeted therapies. Inhibition of angiogenesis and cell signaling emerged as cornerstones of treatment with the approval of bevacizumab and several pan-kinase and tyrosine kinase inhibitors. Though effective, their use has been limited by low rates of durable response, resistance, and side effects. The immunotherapy revolution of the past decade has led to immunotherapy-based combination regimens such as ipilimumab plus nivolumab, pembrolizumab plus axitinib, and avelumab plus axitinib, displacing single agent anti-angiogenic therapy in the first-line setting by demonstrating durable responses and improved survival over sunitinib. These immunotherapy-based combinations define first-line standard of care for aRCC today. The pipeline of second-line agents for consideration in patients who have disease progression despite immunotherapy regimens is robust but still in early stages of development.
    MeSH term(s) Axitinib/therapeutic use ; Carcinoma, Renal Cell/drug therapy ; Humans ; Immunotherapy ; Kidney Neoplasms/drug therapy ; Sunitinib/therapeutic use
    Chemical Substances Axitinib (C9LVQ0YUXG) ; Sunitinib (V99T50803M)
    Language English
    Publishing date 2020-10-13
    Publishing country New Zealand
    Document type Journal Article ; Review
    ZDB-ID 1364202-9
    ISSN 1179-190X ; 1173-8804
    ISSN (online) 1179-190X
    ISSN 1173-8804
    DOI 10.1007/s40259-020-00449-4
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Circulating biomarker correlates of left atrial size and myocardial extracellular volume fraction among persons living with and without HIV.

    Peterson, Tess E / Landon, Christian / Haberlen, Sabina A / Bhondoekhan, Fiona / Plankey, Michael W / Palella, Frank J / Piggott, Damani A / Margolick, Joseph B / Brown, Todd T / Post, Wendy S / Wu, Katherine C

    BMC cardiovascular disorders

    2022  Volume 22, Issue 1, Page(s) 393

    Abstract: Background: Infection with human immunodeficiency virus (HIV) is associated with higher risk for myocardial disease despite modern combination antiretroviral therapy (cART). Factors contributing to this excess risk, however, remain poorly characterized. ...

    Abstract Background: Infection with human immunodeficiency virus (HIV) is associated with higher risk for myocardial disease despite modern combination antiretroviral therapy (cART). Factors contributing to this excess risk, however, remain poorly characterized. We aimed to assess cross-sectional relationships between elevations of left atrial volume index (LAVI) and myocardial extracellular volume (ECV) fraction that have been reported in persons living with HIV and levels of circulating biomarkers of inflammation, fibrosis, and myocyte stretch among persons living with and without HIV (PLWH, PLWOH).
    Methods: Participants from three cohorts of PLWH and PLWOH underwent cardiovascular magnetic resonance imaging for measurement of LAVI and ECV. Levels of circulating proteins (IL-6, sCD14, galectin-3, NT-proBNP, GDF-15, TIMP-2, MMP-2, and hsTnI) were measured using immunoassays. Associations were assessed using logistic and linear regression, adjusting for demographics, substance use, and clinical characteristics.
    Results: Among 381 participants with and without HIV, median age (IQR) was 55.1 (51.2, 58.4) years, 28% were female, 69% were Black, and 46% were current smokers. Sixty-two percent were PLWH (n = 235), of whom 88% were receiving cART and 72% were virally suppressed. PLWH had higher levels of sCD14 (p = < 0.001), GDF-15 (p = < 0.001), and NT-proBNP (p = 0.03) compared to PLWOH, while levels of other biomarkers did not differ by HIV serostatus, including IL-6 (p = 0.84). Among PLWH, higher sCD14, GDF-15, and NT-proBNP were also associated with lower CD4 + cell count, and higher NT-proBNP was associated with detectable HIV viral load. NT-proBNP was associated with elevated LAVI (OR: 1.79 [95% CI: 1.31, 2.44]; p < 0.001) with no evidence of effect measure modification by HIV serostatus. Other associations between HIV-associated biomarkers and LAVI or ECV were small or imprecise.
    Conclusions: Our findings suggest that elevated levels of sCD14, GDF-15, and NT-proBNP among PLWH compared to PLWOH observed in the current cART era may only minimally reflect HIV-associated elevations in LAVI and ECV. Future studies of excess risk of myocardial disease among contemporary cohorts of PLWH should investigate mechanisms other than those connoted by the studied biomarkers.
    MeSH term(s) Biomarkers ; Cardiomyopathies ; Female ; Growth Differentiation Factor 15 ; HIV Infections/complications ; HIV Infections/diagnosis ; HIV Infections/drug therapy ; Heart Atria/diagnostic imaging ; Humans ; Interleukin-6 ; Lipopolysaccharide Receptors ; Male ; Middle Aged ; Natriuretic Peptide, Brain ; Peptide Fragments
    Chemical Substances Biomarkers ; Growth Differentiation Factor 15 ; Interleukin-6 ; Lipopolysaccharide Receptors ; Peptide Fragments ; Natriuretic Peptide, Brain (114471-18-0)
    Language English
    Publishing date 2022-09-03
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Research Support, N.I.H., Extramural
    ZDB-ID 2059859-2
    ISSN 1471-2261 ; 1471-2261
    ISSN (online) 1471-2261
    ISSN 1471-2261
    DOI 10.1186/s12872-022-02835-y
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article: Prognostic value of galectin-1 and galectin-3 expression in localized urothelial bladder cancer.

    Zhu, Jason / Livasy, Chad / Donahue, Erin E / Symanowski, James T / Grigg, Claud M / Brown, Landon C / Matulay, Justin T / Kearns, James T / Raghavan, Derek / Burgess, Earle F / Clark, Peter E

    Translational andrology and urology

    2023  Volume 12, Issue 2, Page(s) 228–240

    Abstract: Background: Galectin-1 (Gal-1) and Galectin-3 (Gal-3) are carbohydrate binding proteins with a wide range of biological activity, including regulation of cellular adhesion, proliferation, and apoptosis in solid tumors. Prior small studies have reported ... ...

    Abstract Background: Galectin-1 (Gal-1) and Galectin-3 (Gal-3) are carbohydrate binding proteins with a wide range of biological activity, including regulation of cellular adhesion, proliferation, and apoptosis in solid tumors. Prior small studies have reported that Gal-3 expression is associated with progression of disease in urothelial carcinoma (UC), from non-muscle invasive UC progression to muscle invasive UC. We assessed Gal-1 and Gal-3 protein expression H-score utilizing a tissue microarray (TMA) created from 301 cystectomy specimens.
    Methods: Immunohistochemistry for Gal-1 and Gal-3 was performed on TMA generated from tumor blocks from chemotherapy naïve cystectomy specimens. The variable of interest, H-score, was defined as the product of the percentage of cells staining positive (0-100) and intensity score (0-3) scored by a single pathologist. Survival end points were analyzed using Kaplan-Meier and Cox Proportional Hazards methods. Clinical data including Charlson Comorbidity Index (CCI), pathologic tumor (T) stage, tumor size, node stage, and surgical margins, were included in multivariable analysis.
    Results: We found that Gal-1 and Gal-3 expression correlated with intratumoral T stage (median Gal-1 H-score was 0 across non-invasive tissue types and 200 in invasive, P<0.01 and median Gal-3 score was 270 across non-invasive tissue types and 70 in invasive, P<0.01). However, the highest intratumoral H-score per cystectomy core did not independently predict for recurrence-free survival (RFS) (Gal-1: HR =1.02, P=0.44, Gal-3: HR =1.01, P=0.65) or OS (Gal-1: HR =1.02, P=0.44, Gal-3: HR =1.01, P=0.72) in this cohort. Significant intratumoral heterogeneity was present for both Gal-1 and Gal-3, with an average difference between the highest and lowest H score was 95 for Gal-1 and 109 for Gal-3 for cystectomy specimens with more than one biopsy.
    Conclusions: Gal-1 and Gal-3 H-score per bladder did not independently predict for RFS or OS. Intra-tumoral Gal-1/Gal-3 heterogeneity complicates the use of Gal-1 and Gal-3 expression as a prognostic biomarker. Future studies should consider the evaluation of serum and urinary galectins as an approach to mitigate tumor heterogeneity.
    Language English
    Publishing date 2023-02-07
    Publishing country China
    Document type Journal Article
    ZDB-ID 2851630-8
    ISSN 2223-4691 ; 2223-4691 ; 2223-4683
    ISSN (online) 2223-4691
    ISSN 2223-4691 ; 2223-4683
    DOI 10.21037/tau-22-494
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Can RECIST response predict success in phase 3 trials in men with metastatic castration-resistant prostate cancer?

    Brown, Landon C / Sonpavde, Guru / Armstrong, Andrew J

    Prostate cancer and prostatic diseases

    2018  Volume 21, Issue 3, Page(s) 419–430

    Abstract: Background: Intermediate endpoints are needed in early phase studies of men with metastatic castration-resistant prostate cancer (mCRPC) that can reliably predict success in phase 3 trials. Among men with measurable disease, objective response may ... ...

    Abstract Background: Intermediate endpoints are needed in early phase studies of men with metastatic castration-resistant prostate cancer (mCRPC) that can reliably predict success in phase 3 trials. Among men with measurable disease, objective response may provide information as to whether a treatment is likely to be successful.
    Methods: We conducted a systematic review of systemic agents that have proceeded to phase 3 trials in men with mCRPC and examined the relationship between improvements in measurable disease response in phase 2 trials and successful phase 3 trials leading to regulatory approval. Only trials that included men with radiographically measurable disease were included.
    Results: We examined 31 eligible mCRPC phase 3 trials between 1992 and 2017 and 29 of the preceding phase 2 trials for RECIST responses. Measurable tumor responses in phase 2 trials were higher for successful therapies in phase 3 trials in chemotherapy-naive men with mCRPC, but were less correlated with success in trials investigating docetaxel combination regimens or the post chemotherapy mCRPC setting. Many failed agents did not produce higher than expected response rates over control arms; however, several agents such as anti-angiogenic therapies or orteronel produced higher than expected responses without survival benefit.
    Conclusions: Objective responses in men with mCRPC may be associated with prolonged survival, but this association is mechanism dependent and inconsistent across trials or disease states. These data support considering RECIST response as a supportive but not sole endpoint in phase 2 trials to support launching phase 3 trials.
    MeSH term(s) Antineoplastic Agents/therapeutic use ; Clinical Trials, Phase II as Topic ; Clinical Trials, Phase III as Topic ; Humans ; Male ; Prostate/diagnostic imaging ; Prostate/pathology ; Prostatic Neoplasms, Castration-Resistant/diagnostic imaging ; Prostatic Neoplasms, Castration-Resistant/drug therapy ; Prostatic Neoplasms, Castration-Resistant/mortality ; Prostatic Neoplasms, Castration-Resistant/pathology ; Response Evaluation Criteria in Solid Tumors ; Survival Analysis ; Treatment Outcome
    Chemical Substances Antineoplastic Agents
    Language English
    Publishing date 2018-06-01
    Publishing country England
    Document type Journal Article ; Meta-Analysis ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't ; Systematic Review
    ZDB-ID 1419277-9
    ISSN 1476-5608 ; 1365-7852
    ISSN (online) 1476-5608
    ISSN 1365-7852
    DOI 10.1038/s41391-018-0049-6
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top